Health Care & Life Sciences » Biotechnology | Genetic Signatures Ltd.

Genetic Signatures Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
1,728.50
2,659.10
3,026.60
2,670.60
3,253.80
Depreciation, Depletion & Amortization
103.90
205.60
399.30
478.70
631.80
Other Funds
289.30
151.00
590.30
263.90
193.00
Funds from Operations
1,335.30
2,302.50
2,037.00
1,928.10
2,429.00
Changes in Working Capital
19.40
492.60
535.40
643.80
1,264.50
Net Operating Cash Flow
1,354.70
2,795.10
2,572.30
2,571.90
3,693.60
Capital Expenditures
380.80
551.70
371.20
1,011.60
519.40
Net Investing Cash Flow
380.80
551.70
371.20
1,011.60
519.40
Net Financing Cash Flow
3,440.80
6,955.80
46.00
14,230.40
-
Net Change in Cash
1,705.20
3,609.00
2,897.40
10,628.70
4,238.20
Free Cash Flow
1,735.60
3,346.80
2,943.50
3,583.50
4,212.90
Change in Capital Stock
3,440.80
6,955.80
46.00
14,230.40
-
Exchange Rate Effect
-
-
-
18.20
25.30

About Genetic Signatures

View Profile
Address
7 Eliza Street
Newtown New South Wales (NSW) 2042
Australia
Employees -
Website http://www.geneticsignatures.com
Updated 07/08/2019
Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. Its molecular diagnostics, 3Base, provides high-volume hospital and pathology laboratories the ability to screen wide array of infectious pathogens. The firm also designs and manufactures suite of real-time polymerase chain reaction based products for the routine detection of infectious diseases under the EasyScreen brand.